| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Stephen Buckley Jr. last filed a Form 4 in February 2019, as Director at ELDN. The filings on record cover 2 companies. Stephen Buckley Jr.'s net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 11,000 shares of ELDN. Net of sales, the ELDN filings show accumulation of 11,000 shares.
Stephen Buckley Jr. has 11 Form 4 filings on record from January 2015 to February 2019, across 2 companies: Director at Enanta Pharmaceuticals (ENTA), 2015–2019; Director at Eledon Pharmaceuticals (ELDN), 2015–2016.
The 12 reported transactions were 8 option or other derivative awards and 4 open-market purchases.
Counted by filing, the open-market trades come to 3 purchases worth about $114K and no sales.
The largest open-market purchase was 8,000 shares of ELDN at an average $5.74 on March 15, 2016, about $46K.
Shares as reported in the last Form 4 for each company; the most recent is from February 2019. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.